-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Insmed, Maintains $207 Price Target

Benzinga·07/10/2026 12:36:14
语音播报
Guggenheim analyst Vamil Divan reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $207 price target.